Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02110576 · ClinicalTrials.gov registry record
Procedure For The Reference Range Study For Absolute MA
A clinical trial, sponsored by Haemonetics Corporation.
- Completed
- Registry status
- 161
- Enrollment target
NCT02110576: Completed study, sponsored by Haemonetics Corporation.
NCT02110576 is a clinical trial that has completed, run by Haemonetics Corporation. The registered enrollment target is 161 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02110576 has completed, sponsored by Haemonetics Corporation.
- COMPLETED
- Registry status
- 161 participants
- Enrollment target
Study Summary
CLSI guidelines shall be followed to gather data from a minimum of one hundred and twenty normal donors to create reference intervals for various Haemonetics reagents. Venous blood from a minimum of 146 reference subjects shall be tested. Blood from 160 donors will be drawn at the study site to account for aberrant or outlying data excluded for technical or other reasons.
Primary Outcome
Reference ranges will be completed on 50 parameters sample type combinations for which 160 donors will be enrolled.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 161 participants |
| Start Date | 2014-05 |
| Est. Completion | 2015-03 |
What the finished NCT02110576 record still lists
NCT02110576 is an observational study that tracks outcomes without assigning an intervention. The registered 161 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02110576 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02110576 about?
NCT02110576 is a clinical study titled "Procedure For The Reference Range Study For Absolute MA". CLSI guidelines shall be followed to gather data from a minimum of one hundred and twenty normal donors to create reference intervals for various Haemonetics reagents. Venous blood from a minimum of 146 reference subjects shall be tested. Blood from 160 donors will be drawn at the study site to acco...
What is the current status of trial NCT02110576?
This trial is currently completed. The enrollment target is 161 participants. The study started on 2014-05. Estimated completion is 2015-03.
Who is sponsoring clinical trial NCT02110576?
This trial is sponsored by Haemonetics Corporation, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06391034 · 161 participants · Phase 2
Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer
- NCT06546670 · 161 participants · Phase 1
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
- NCT06616766 · 161 participants · Phase 1
A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946
- NCT06752356 · 161 participants · Phase 3
A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia